Literature DB >> 10599811

Marginally improved detection of GM1 antibodies by Covalink ELISA in multifocal motor neuropathy.

M Carpo1, S Allaria, G Scarlato, E Nobile-Orazio.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10599811     DOI: 10.1212/wnl.53.9.2206

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

1.  Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.

Authors:  F Galban-Horcajo; A M Fitzpatrick; A J Hutton; S M Dunn; G Kalna; K M Brennan; S Rinaldi; R K Yu; C S Goodyear; H J Willison
Journal:  Eur J Neurol       Date:  2012-06-22       Impact factor: 6.089

Review 2.  Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors:  Thomas B Toothaker; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

3.  Long term disability and social status change after Guillain-Barré syndrome.

Authors:  A Bersano; M Carpo; S Allaria; D Franciotta; A Citterio; E Nobile-Orazio
Journal:  J Neurol       Date:  2005-08-17       Impact factor: 4.849

4.  Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block.

Authors:  E Nobile-Orazio; A Cappellari; N Meucci; M Carpo; F Terenghi; A Bersano; A Priori; S Barbieri; G Scarlato
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

Review 5.  Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants.

Authors:  Mazen M Dimachkie; Richard J Barohn; Jonathan Katz
Journal:  Neurol Clin       Date:  2013-02-16       Impact factor: 3.806

6.  Asymmetric Acquired Demyelinating Polyneuropathies: MMN and MADSAM.

Authors:  Jonathan S. Katz; David S. Saperstein
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.972

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.